Oct. 2 at 1:01 PM
$PHIO Keep in mind that Renmark is a roadshow, it is a pitch to introduce the company to investors to buy shares. In the Q&A, Bitterman may give some news (no adverse events in cohort 5 would be huge), but, traditionally has not. The pitch is legitimate, not a fraud, PHIO has a tremendous future and great potential. Intasyl will likely be one of 5-8 compounds (5 to 10 years from now) in a treatment regimen for solitary, solid tumors.
Historically, data has been released two to four weeks following the Renmark Pitch. We believe that late October is a reasonable time period for data release.
